Contact us
[email protected] | |
3275638434 | |
Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Author(s)
Liza Shahnaz, Zainal Abidin Muhja, Ade Cici Suciati
Full-Text PDF XML 387 Views
DOI:10.17265/1548-6605/2021.06.003
Affiliation(s)
Borneo University of Tarakan, Tarakan, Indonesia
ABSTRACT
With the current development of the COVID-19 vaccine within two years of the outbreak, science has scored a remarkable milestone. US pharmaceutical companies, such as Pfizer, Moderna, Oxford/AstraZeneca, and Novavax have led the global race to mass-produce the most effective vaccine against COVID-19, followed by Russia and China. However, developing countries still cannot afford the U.S.-made vaccine on a large scale, which is currently considered the most effective. The challenge now is to make all these vaccines quickly, reasonably, and equally accessible to people worldwide. While rich countries have bought vaccine doses, low-income countries are still under-resourced. The development of distribution and access to vaccines is worrying, considering that many countries may find it difficult to buy or make their vaccines, so cooperation between governments and international institutions is needed to solve the problem. This study analyzes how countries and international institutions as the prominent legal subjects in international law work together to achieve equitable and fair distribution and access globally following international law.
KEYWORDS
access and distribution to COVID-19 vaccine, state responsibility, international organization
Cite this paper
References